Moderna Cancer Vaccine Data Confirms 42% Recurrence Cut
Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings in MRNA shares.
Markets
Delayed · 11:48 UK
Topic
Every Financial News story tagged MRNA, newest first.
1–5 of 5
Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings in MRNA shares.
A melanoma vaccine data leak wiped $24bn off Moderna before its Madrid presentation, despite a statistically strong Phase 3 result.
S&P 500 weekly gains hit 1.3% as telecom towers and utilities rallied while Arm, Intel and Seagate led a chip-sector slide.
Moderna's Nasdaq-100 inclusion takes effect 9 October 2026, replacing Warner Bros. Discovery, even as the biotech posts fresh quarterly losses.
This week's market recap: Nasdaq gains 2.36% as chip and AI names surge, while Gen Digital and Paychex lead a software rout. Yields climb.